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Recent progress in the understanding of psoriasis has shown that the regulation of local and systemic cytokines plays an important
role in its pathogenesis. The most often used psoriasis score is the psoriasis area and severity index (PASI). A simple laboratory
test from a blood sample would be an attractive, patient-independent, and observer-independent marker of disease severity. To this
end, we evaluated the association of serum levels of some proinﬂammatory cytokines in vivo and their correlation with severity of
psoriasis. The serum levels of cytokines levels were determined with the use of the ELISA method. All mean values except IL-17
levels of patients were signiﬁcantly higher than those of controls. There was a signiﬁcant correlation between serum levels of IFN-γ,
IL-12, IL-17, and IL-18, and severity of the disease. Psoriasis can be described as a T-cell-mediated disease, with a complex role for
a variety of cytokines, which has led to the development of new immunomodulatory therapies. In this study, serum TNF-α,I F N - γ,
IL-6, IL-8, IL-12, and IL-18 levels were signiﬁcantly higher in active psoriatic patients than in controls. Furthermore, high levels of
IFN-γ, IL-12, and IL-18 correlated with the clinical severity and activity of psoriasis, and those measurements of serum levels of
these cytokines may be objective parameters for the disease severity.
INTRODUCTION
Psoriasis, a common and enigmatic recurrent cuta-
neous disease, has for long been considered a hyper-
proliferation with extremelyincreased rate of epidermal
turnover, and an activated mononuclear inﬁltrate in the
underlyingdermis. Recent progress in the understand-
ing of psoriasis has attributed its pathogenesis to the
important role of T cells. New anti-T lymphocytes im-
munotherapies, and some traditional antipsoriatic med-
ications such as methotrexate,steroids, and cyclosporin A,
have conﬁrmed an important role of the immune sys-
tem in psoriasis [1]. At present, research into psoriasis
is dominated by thehypothesis that it is an immunolog-
ical disorder described by abnormal keratinocyte prolifer-
ation mediated through T lymphocytes [2, 3, 4]. Autoim-
mune disorders and inﬂammatory reactions are currently
segregated into cell-mediated Th1 or Th2 categories. Pso-
riasis is associated with an overexpression of proinﬂam-
matory cytokines produced by Th1 cells and relative un-
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derexpression of Th2 cytokines [5]. Today,the roles of cy-
tokines in the pathogenesis of psoriasis are investigated.
However, in extrapolating the biologic these activities of
cytokines demonstrated in the in vitro models to the in
vivo situation in psoriasis, it is clear that there may be
much more complex interactions among individual cy-
tokines in vivo than expected from the in vitro mod-
els.
There does not yet exist an objective laboratory pa-
rameter to measure the severity of psoriasis. Th1 cy-
tokines are found in high levels both in lesional skin and
in the peripheral blood in the psoriatic patients. Serum is
easy to obtain from patients and small amounts of it will
be suﬃcient. Thus, the measurement of serum cytokines
may allow for better monitoring and prediction of dis-
ease severity. In this study, we evaluated association with
serum levels of some proinﬂammatory cytokines (IFN-
γ,T N F - α, IL-6, IL-8, IL-12, IL-17, and IL-18) and their
correlation with severity of psoriasis in Turkish popula-
tion. With the understanding of relationships between cy-
tokines, it could be possible to describe the pathogenesis
of the disease. In cases that are diﬃcult to diagnose, and
also in the follow-up of the patients, the assessment of
these diﬀerent parameters in the peripheral blood at the
same time may be of use. Therefore, we also evaluated in
vivo relationships of these cytokines.274 Ozer Arican et al 2005:5 (2005)
Table 1. Mean, minimum-maximum, and median values of serum cytokines levels in psoriatic patients and healthy controls, and the
results of statistical assessments. Values are mean ± SD.
Cytokines Patients Controls
P
(n = 30) (n = 23)
IFN-γ (IU/mL) 0.95 ±0.907 (0.0–3.1, 0.7) 0.42 ±0.465 (0.0–1.5, 0.3) <. 05∗
TNF-α (pg/mL) 25.7 ±10.62 (4.8–44.6, 23.4) 11.2 ±7.31 (0.0–32.5, 11.3) <. 001∗∗
IL-6 (pg/mL) 13.7 ±12.18 (0.0–62.0, 12.6) 4.2 ±5.86 (0.0–12.7, 0.0) <. 001∗
IL-8 (pg/mL) 35.9 ±22.77 (2.8–80.9, 38.4) 12.9 ±13.93 (0.0–50.4, 7.9) <. 001∗∗
IL-12 (pg/mL) 36.6 ±17.93 (2.9–62.4, 33.8) 24.9 ±13.29 (2.9–53.9, 25.8) <. 001∗∗
IL-17 (pg/mL) 8.3 ±3.80 (0.0–13.9, 6.2) 7.4 ±3.76 (0.0–13.4, 6.2) >. 05∗
IL-18 (pg/mL) 88.6 ±36.81 (0.0–124.8, 101.9) 32.7 ±19.39 (0.0–70.0, 26.6) <. 001∗
∗Mann-Whitney U test, ∗∗Student t test.
MATERIALS AND METHODS
Patientsandcontrols
Consecutive patients with psoriasis who had not re-
ceived any prior local or systemic treatment within two
months were included in the study. The diagnosis was
made clinically, based on characteristic plaque-type pso-
riatic lesions. Patients with erythrodermic, pustular, and
only palmoplantar forms of psoriasis, and patients with
psoriatic arthritis were excluded. The severity of psori-
asis was assessed by the psoriasis area and severity in-
dex (PASI) for each patient. The control group was com-
prised of healthy, nonpsoriatic volunteers with no fam-
ily history of psoriasis. Blood, urine, and feces specimens
were collected from both patients and controls for rou-
tine laboratory investigations including blood sedimenta-
tion rate, liver enzymes, blood cell counts, and C-reactive
protein level to exclude organic or metabolic abnormal-
ities and infections at the same time points. A signed
informed consent was taken from all patients and con-
trols.
Serum
Venous blood samples (5–10mL) were taken in vacu-
tainer tubes under sterile conditions from patients and
controls between 08:30–10:30 am. Serum was obtained
from freshly drawn, rapidly centrifugated. Serum was
quickly frozen at −70◦C and stored until processed.
Cytokinesdetections
Serum TNF-α,I F N - γ, IL-6, IL-8, IL-12 (p40 kit), IL-
17, and IL-18 levels were measured by enzyme-linked
immunosorbent assay (ELISA) technique (enzyme-am-
pliﬁed sensitivity immunoassay (EASIA) kits, BioSource
Europe SA, 8 B-1400, Nivelles, Belgium). These assays
detected only human cytokines and the minimum de-
tectable concentrations in our laboratory were 4.8pg/mL
for TNF-α,0 .2IU/mL for IFN-γ,1 .1pg/mL for IL-6,
1.9pg/mLforIL-8,2.9pg/mL for IL-12, 4.6pg/mLforIL-
17, and 16.6pg/mL for IL-18.
Statisticalanalyses
All data were analyzed using the statistical package for
social science (SPSS) 10.0 for Windows program on the
computer. All data were given as mean ± standard de-
viation (SD). Chi-square test was used to compare dif-
ferences between the frequencies. Serum cytokines lev-
els were analyzed using the normality test. The Mann-
Whitney U and Student t test was used to compare mean
values between groups. Spearman rank correlation test
was used for the assessment of correlation. The statistical
signiﬁcance was accepted as P value < 0.05.
RESULTS
A total of 30 patients (18 males, 12 females), of
mean age 35 ± 15.5 (range: 7–79) years, and 23 age-
and sex-matched healthy controls were enrolled in this
study. There were no signiﬁcant diﬀerences in age and
male/female ratio between the patients and controls (P>
0.05). Neither patients nor controls had a history of, or
clinicalorroutinelaboratoryﬁndingsconsistentwith,im-
pairedhepaticorrenalfunction,norparasiticoranyother
infection. The cell counts in whole blood and C-reactive
p r o t e i nl e v e l sw e r ei nn o r m a lr a n g e si ne a c hp a t i e n ta n d
controls. The mean duration of illness for the patients
group was 9 ± 10.1 (range: 1–40) years. The average PASI
score in patients was 9.3 ±8.15 (range: 1.5–33.3).
The mean, minimum, maximum, and median values
of the serum levels of interleukins, TNF-α,a n dI F N - γ of
both groups and statistical results are presented in Table
1. The results also are shown in Figures 1a, 1b, 1c, 1d, 1e,
and1f.AllmeanvaluesexceptIL-17levelsofpatientswere
signiﬁcantly higher than those of controls. There was cor-
relation between serum levels of IFN-γ, IL-12, IL-17, and
IL-18, and severity of the disease. Correlation among dis-
ease severity and serum levels of cytokines are shown in
Table 2.
In healthy controls, there were no correlations among
the serum levels of TNF-α,I F N - γ IL-6, IL-8, IL-12, IL-17,
and IL-18. There was no correlation between age or gen-





























































































































































Figure 1. (a) IFN-γ,( b )T N F - α, (c) IL-6, (d) IL-8, (e) IL-12, and (f) IL-18 serum levels of psoriatic patients and controls in box plot
graphics (◦:o u t l i e r s ) .276 Ozer Arican et al 2005:5 (2005)
Table 2. Correlation among disease severities and serum cytokines levels evaluated by the Spearman rank correlation.
PASI and cytokines Statistical values IFN-γ TNF-α IL-6 IL-8 IL-12 IL-17 IL-18
PASI
r 0.89 −0.29 0.03 −0.06 0.93 0.47 0.86
P 0.00 0.12 0.88 0.75 0.00 0.01 0.00
IFN-γ r — −0.18 0.08 0.04 0.88 0.38 0.78
P —0 .35 0.67 0.82 0.00 0.04 0.00
TNF-α
r —— −0.16 0.18 −0.22 0.12 −0.10
P ——0 .39 0.33 0.24 0.52 0.60
IL-6
r ——— −0.05 −0.10 0.21 0.05
P ———0 .80 0.58 0.27 0.82
IL-8
r ——— — −0.02 −0.02 −0.09
P ——— —0 .94 0.90 0.65
IL-12
r — ————0 .43 0.90
P — ————0 .02 0.00
IL-17
r — —————0 .72
P — —————0 .00
CONCLUSION
Histologically, psoriasis is characterized by marked
keratinocytehyperproliferation,adenseinﬂammatoryin-
ﬁltrate consisting of T cells and neutrophils, and vascular
dilatation and proliferation. The primary defect in psori-
asis patients was believed to be abnormal epidermal cells
proliferation [6]. The very early lesion of psoriasis is char-
acterized by an inﬂammatory inﬁltrate of mononuclear
cells in the upper dermis with only minimal changes in
the epidermis [7]. Thus, systemic eﬀects of circulating cy-
tokines may play an important role in the induction of
epidermal cell proliferation. It was proposed that in nor-
mal skin there could be an interaction between the epi-
dermis and circulating T cells [8]. Recently, abnormal cy-
tokines production is being studied as a possible mecha-
nism in psoriasis.
Cytokines are small, biologically highly active pro-
teins that regulate the growth, function, and diﬀerenti-
ation of cells and help steer the immune response and
inﬂammation [9]. Keratinocytes secrete a number of cy-
tokines and chemokines that either activate or suppress
immune responses [10]. However, precise mechanism of
their involvement in psoriasis remains unclear. Any lo-
cal or systemic stimulus may stimulate keratinocyte cy-
tokines production [11]. The pattern of cytokine expres-
sion suggests that Th1 cells may mediate or maintain dis-
ease [12, 13, 14]. Our data conﬁrmed previously pub-
lisheddatathattheTh1cytokines(TNF-α,IFN-γ,andIL -
12) and some proinﬂammatory cytokines (such as IL-6,
IL-8, and IL-18) are inﬂuenced in the serum of psoriatic
patients. Moreover, we found signiﬁcant correlation be-
tween severity of the disease and serum levels of IFN-γ,
IL-12, IL-17, and IL-18. Additionally, our data showed
that serum levels of these cytokines did not correlate with
age or gender.
The previous studies demonstrated a signiﬁcant in-
creaseinIFN-γ [15,16,17,18],TNF-α[19,20,21,22,23],
IL-6 [19, 22, 24], IL-8 [15, 19, 23, 25, 26], and IL-18
[27] in the serum of psoriatic patients compared to the
healthy controls. The exact role of TNF-α in the path-
omechanism of psoriasis is still unclear, but anti-TNF-α
therapy is highly eﬀective in psoriasis indicating that this
cytokine has, together with IFN-γ, a central role in the
pathogenesis. IFN-γ and TNF-α induce IL-6, IL-8, IL-12,
andIL-18andconstituteanimportantlinkinthecytokine
network in the pathogenesis of psoriasis [5]. Moreover,
the intradermal administration of IFN-γ into nonlesional
skin of psoriatic patients causes the appearance of lesions
at the inoculation site [10]. IL-6 mediates T-cell activa-
tion,stimulatesproliferationofkeratinocytes[28],and,at
the beginning of acute inﬂammation, mediates the acute
phase responses [29]. Elevated amounts of IL-8 have been
detected in psoriatic lesional skin [30]. Many studies in-
dicate that IL-8 may be involved in the pathomechanism
of psoriasis. In fact, data currently available suggest that
thiscytokineexertsacriticalroleasapotentchemoattrac-
tant for neutrophils and T lymphocytes, as well as a factor
prompting keratinocyte proliferation [10]. IL-12 plays a
major role in the development of Th1-cell-mediated im-
mune responses. Besides, in situ IL-12 may also have a
role in the induction of new psoriatic skin lesions [31].
Contrary to our ﬁnding, Jacob et al reported that a serum
mean IL-12 level was decreased in patients with psori-
asis [15]. This diﬀerent result may stem from the vari-
ous laboratory methods used. We measured p40 subunit
of IL-12. IL-12 and IL-23 are heterodimers that share a
common p40 chain. Nevertheless, an antibody to the hu-
man IL-12/p40 (anti-IL-12p40) was reported to have sig-
niﬁcant eﬀect in psoriatic patients [32]. IL-18 has an im-
portant role in cellular adhesion, being the ﬁnal common
pathway used by IL-1 and TNF-α that leads to ICAM-12005:5 (2005) Serum Cytokines in Psoriasis and Disease Severity 277
(intercellular adhesion molecule 1) expression [33]. IL-18
receptor expression is upregulated by IL-12, and thereby
these two cytokines synergize to stimulate IFN-γ release
[34, 35]. IL-18 acts on dendritic cells synergistically with
IL-12, which is also produced by the dendritic cells,
thereby greatly increasing the IFN-γ production [36]. The
data support the important proinﬂammatory role of IFN-
γ and TNF-α in the clinical manifestation of psoriasis. We
could not conclude why high serum levels of TNF-α had
no correlation with PASI scores in patients with psoria-
sis.
We did not ﬁnd any study about serum levels of IL-
17 in psoriasis in the literature. Our results may be the
ﬁrst report on serum levels of IL-17 in patients with pso-
riasis. IL-17 expression could not be detected in normal
skin, but was found in psoriatic lesional skin [37]. We
found that serum IL-17 levels were slightly higher in pso-
riatic patients than controls, although not signiﬁcant. IL-
17, which is produced by activated CD4+ T cells, syner-
gizeswithIFN-γ to enhance the production of proinﬂam-
matory cytokines by human keratinocytes, including IL-6
and IL-8, thereby increasing the migration of T cells to
the skin. IL-17 can also be considered a proinﬂammatory
cytokine. This eﬀect of IL-17 is further potentiated when
IFN-γ is also present, and increase in IL-6 and IL-8 se-
cretion can be observed after costimulation [38]. In vivo
data in the biological role of IL-17 are even more limited
[39]. It is not clear why we found IL-17 levels normal but
it had a signiﬁcant correlation with PASI in our psoriatic
patients. Further new studies would be beneﬁcial to con-
ﬁrm these results and to understand the pathogenesis of
psoriasis in vivo.
Psoriasis can be described as a T-cell-mediated dis-
ease, with a complex role for a variety of cytokines and
otherfactors.InteractionbetweenTlymphocytesandker-
atinocytes, via cytokines, is likely to play a pivotal role
in the pathogenic process in psoriasis. The impact of this
study is the signiﬁcant correlation among high serum lev-
els of IFN-γ, IL-12, and IL-18 in psoriatic patients. Sim-
ilarly, Piskin et al showed that expressions of IFN-γ in-
ducers IL-12, IL-18, and IL-23 in lesional skin have de-
creased after narrowband ultraviolet-B therapy in psori-
asis [41]. This ﬁnding indicates that the production of
these cytokines, with similar biologic properties and ac-
tivity spectra, may be strictly regulated by one another.
How the synthesis of this complex array of cytokines is
coordinated and regulated in vivo is an essential question
f o rf u r t h e rw o r k .
In the present study, serum TNF-α,I F N - γ, IL-6, IL-8,
IL-12, and IL-18 levels were signiﬁcantly higher in the pa-
tients with psoriasis than in healthy controls. Cytokines
play an important role in the pathogenesis of psoria-
sis. When cytokines levels are measured in serum, it is
not possible to determine the origin of these cytokines.
The serum cytokine concentrations are altered by sev-
eral processes like the production, tissue/cellular depo-
sition, degradation, and elimination of these molecules;
furthermore other tissue sources of cytokine production
might exist beside the circulating T cells. The origin of
circulating cytokines in blood serum in psoriatic patients
isnotclear.Toachievethecytokineconcentrationthatcan
induce biological responses at distant skin lesions, huge
amounts of free cytokines that induce generalized inﬂam-
mation are required. Thus, the receptors on psoriatic ker-
atinocytes may be more sensitive to these cytokines. Fur-
thermore,wedemonstratedherethathighlevelsofIFN-γ,
IL-12, and IL-18 correlated with PASI and those measure-
ments of serum levels of these cytokines may be an objec-
tive parameter for psoriasis activity and clinical severity.
These data conﬁrm the hypothesis that psoriasis might
be considered as a true systemic disease with particular
immunologic pathways. An array of these cytokines may
be considered as useful follow-up markers for monitoring
psoriatic patients and optimizing therapeutic strategies in
daily medical practice. In addition, to measure these cy-
tokines’ levels in serum, if there is a doubt in skin histol-
ogy ,itwouldbemoreusefultodiﬀerentiatepsoriasisfrom
other skin diseases, such as seborrheic dermatitis or para-
psoriasis.
The importance of serum cytokines in dermatology is
increasing dramatically. The new ELISA methods are use-
ful with their high speciﬁcity and good standardizability
againstthehighcosts[40].Unfortunately,thecytokineas-
sayresultsmayvaryduetothemethodsusedforcytokines
detection and their sensitivities, interferences due to dif-
ferent drugs used, and the eﬀect of concomitant patholo-
gies [17]. The skin, largest organ of the body, is the site
of more than 50 diﬀerent clinically recognizable inﬂam-
matory dermatological diseases. Thus, the exact role of
serum cytokines needs to be clariﬁed and further stud-
ies are required in the pathogenesis of cutaneous disor-
ders including psoriasis. However, the question remains
whether cytokine abnormalities represent the egg or the
chicken in dermatologic disorders. It appears likely that
these changes are not the cause, but the consequence of,
the dermatological diseases. Understanding the in vivo
immunological cascade as described above is crucial for
the development of biological therapies. Whether block-
ing these cytokine activities, either by antibodies or spe-
ciﬁc inhibitors, may open new therapeutic aspects has
yet to be demonstrated [42, 43]. Until other inﬂamma-
tory skin diseases are studied, we cannot speculate on the
speciﬁcity of these results, and further investigations will
be required to deﬁne the role of serum proinﬂammatory
cytokines in the pathogenesis and their correlation with
clinical severity of psoriasis.
REFERENCES
[1] Lowes MA, Lew W, Krueger JG. Current concepts
in the immunopathogenesis of psoriasis. Dermatol
Clin. 2004;22(4):349–369.
[2] Bos JD, De Rie MA. The pathogenesis of psoriasis:
immunological facts and speculations. Immunol To-
day. 1999;20(1):40–46.278 Ozer Arican et al 2005:5 (2005)
[3] Griﬃths CEM. The immunological basis of psori-
asis. J Eur Acad Dermatol Venereol. 2003;17(suppl
2):1–5.
[4] Chamian F, Krueger JG. Psoriasis vulgaris: an in-
terplay of T lymphocytes, dendritic cells, and in-
ﬂammatory cytokines in pathogenesis. Curr Opin
Rheumatol. 2004;16(4):331–337.
[5] Gudjonsson JE, Johnston A, Sigmundsdottir H,
Valdimarsson H. Immunopathogenic mechanisms
in psoriasis. Clin Exp Immunol. 2004;135(1):1–8.
[6] FryL.Psoriasis.BrJDermatol.1988;119(4):445–461.
[7] Lever WF, Schaumburg-Lever G. Histopathology of
the Skin. Philadelphia, Pa: JB Lippincott; 1975:135–
146.
[8] McKenzie RC, Sauder DN. The role of keratinocyte
cytokines in inﬂammation and immunity. JI n v e s t
Dermatol. 1990;95(suppl 6):105S–107S.
[9] Thomson A. The Cytokine Handbook. 3rd ed. New
York, NY: Academic Press; 1998.
[10] Bonifati C, Ameglio F. Cytokines in psoriasis. Int J
Dermatol. 1999;38(4):241–251.
[11] Nickoloﬀ BJ, Karabin GD, Barker JN, et al. Cellu-
lar localization of interleukin-8 and its inducer, tu-
mor necrosis factor-alpha in psoriasis. Am J Pathol.
1991;138(1):129–140.
[12] Prinz JC. Which T cells cause psoriasis? Clin Exp
Dermatol. 1999;24(4):291–295.
[13] UyemuraK,YamamuraM,FivensonDF,ModlinRL,
Nickoloﬀ BJ. The cytokine network in lesional and
lesion-free psoriatic skin is characterized by a T-
helper type 1 cell-mediated response. JI n v e s tD e r -
matol. 1993;101(5):701–705.
[14] De Rie MA, Goedkoop AY, Bos JD. Overview of pso-
riasis. Dermatol Ther. 2004;17(5):341–349.
[15] Jacob SE, Nassiri M, Kerdel FA, Vincek V. Simulta-
neous measurement of multiple Th1 and Th2 serum
cytokines in psoriasis and correlation with disease
severity. Mediators Inﬂamm. 2003;12(5):309–313.
[16] El Barnawi NY, Giasuddin ASM, Ziu MM, Singh
M. Serum cytokine levels in psoriasis vulgaris. Br J
Biomed Sci. 2001;58(1):40–44.
[17] Szegedi A, Aleksza M, Gonda A, et al. Elevated
rate of Thelper1 (T(H)1) lymphocytes and serum
IFN-γ levels in psoriatic patients. Immunol Lett.
2003;86(3):277–280.
[18] Gomi T, Shiohara T, Munakata T, Imanishi K, Na-
gashima M. Interleukin 1α, tumor necrosis factor
α, and interferon γ in psoriasis. Arch Dermatol.
1991;127(6):827–830.
[19] Abanmi A, Al Harthi F, Al Agla R, Khan HA, Tariq
M. Serum levels of proinﬂammatory cytokines in
psoriasis patients from Saudi Arabia. Int J Dermatol.
2005;44(1):82–83.
[20] Mussi A, Bonifati C, Carducci M, et al. Serum TNF-
alpha levels correlate with disease severity and are
reduced by eﬀective therapy in plaque-type psori-
asis. J Biol Regul Homeost Agents. 1997;11(3):115–
118.
[21] Chodorowska G. Plasma concentrations of IFN-
gamma and TNF-alpha in psoriatic patients be-
fore and after local treatment with dithranol oint-
ment.JEurAcadDermatolVenereol.1998;10(2):147–
151.
[22] Mizutani H, Ohmoto Y, Mizutani T, Murata M,
Shimizu M. Role of increased production of mono-
cytes TNF-α,I L - 1 β and IL-6 in psoriasis: relation
to focal infection, disease activity and responses to
treatments. JD e r m a t o lS c i .1997;14(2):145–153.
[ 2 3 ]O k u b oY ,K o g aM .P e r i p h e r a lb l o o dm o n o c y t e si n
psoriatic patients overproduce cytokines. JD e r m a t o l
Sci. 1998;17(3):223–232.
[24] Szepietowski JC, Bielicka E, Nockowski P, Noworol-
ska A, Wasik F. Increased interleukin-7 levels in the
sera of psoriatic patients: lack of correlations with
interleukin-6 levels and disease intensity. Clin Exp
Dermatol. 2000;25(8):643–647.
[25] Biasi D, Carletto A, Caramaschi P, et al. Neutrophil
functions and IL-8 in psoriatic arthritis and in
cutaneous psoriasis. Inﬂammation. 1998;22(5):533–
543.
[26] Pietrzak A, Koziol-Montewka M, Lecewicz-Torun B,
Krasowska D. Is there any correlation between the
total number of neutrophils in plasma and concen-
trationofinterleukin-8inpsoriaticpatients?Med Sci
Monit. 2000;6(5):867–870.
[27] Gangemi S, Merendino RA, Guarneri F, et al. Serum
levels of interleukin-18 and s-ICAM-1 in patients af-
fected by psoriasis: preliminary considerations. JE u r
Acad Dermatol Venereol. 2003;17(1):42–46.
[28] Sehgal PB. Interleukin-6: molecular pathophysiol-
ogy. J Invest Dermatol. 1990;94(suppl 6):2S–6S.
[29] Ishihara K, Hirano T. IL-6 in autoimmune disease
and chronic inﬂammatory proliferative disease. Cy-
tokine Growth Factor Rev. 2002;13(4-5):357–368.
[30] Sticherling M, Sautier W, Schroder JM, Christophers
E. Interleukin-8 plays its role at local level in psoria-
sis vulgaris. Acta Derm Venereol. 1999;79(1):4–8.
[31] Yawalkar N, Karlen S, Hunger R, Brand CU, Braa-
then LR. Expression of interleukin-12 is increased in
psoriatic skin. J Invest Dermatol. 1998;111(6):1053–
1057.
[32] Kauﬀman CL, Aria N, Toichi E, et al. A phase I
study evaluating the safety, pharmacokinetics, and
clinical response of a human IL-12 p40 antibody
in subjects with plaque psoriasis. J Invest Dermatol.
2004;123(6):1037–1044.
[33] Borish LC, Steinke JW. Cytokines and chemokines. J
AllergyClinImmunol.2003;111(suppl2):S460–S475.
[34] Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 up-
regulates IL-18 receptor expression on T cells, Th1
cells, and B cells: synergism with IL-18 for IFN-γ
production. JI m m u n o l .1998;161(7):3400–3407.
[35] Fantuzzi G, Reed DA, Dinarello CA. IL-12-induced
IFN-gammaisdependentoncaspase-1processingof
the IL-18 precursor. JC l i nI n v e s t .1999;104(6):761–
767.2005:5 (2005) Serum Cytokines in Psoriasis and Disease Severity 279
[36] DinarelloCA.IL-18:aTH1-inducing,proinﬂamma-
tory cytokine and new member of the IL-1 family. J
Allergy Clin Immunol. 1999;103(1 pt 1):11–24.
[37] Witowski J, Ksiazek K, Jorres A. Interleukin-17: a
mediator of inﬂammatory responses. Cell Mol Life
Sci. 2004;61(5):567–579.
[38] Teunissen MBM, Koomen CW, de Waal Malefyt R,
WierengaEA,BosJD.Interleukin-17andinterferon-
γ synergize in the enhancement of proinﬂammatory
cytokine production by human keratinocytes. JI n -
vest Dermatol. 1998;111(4):645–649.
[39] Spriggs MK. Interleukin-17 and its receptor. JC l i n
Immunol. 1997;17(5):366–369.
[40] Piskin G, Tursen U, Sylva-Steenland RMR, Bos JD,
Teunissen MB. Clinical improvement in chronic
plaque-type psoriasis lesions after narrow-band
UVBtherapyisaccompaniedbyadecreaseintheex-
pression of IFN-γ inducers—IL-12, IL-18 and IL-23.
Exp Dermatol. 2004;13(12):764–772.
[41] Asadullah K, Sterry W, Volk HD. Analysis of cy-
tokine expression in dermatology. Arch Dermatol.
2002;138(9):1189–1196.
[42] Williams JDL, Griﬃths CEM. Cytokine block-
ing agents in dermatology. Clin Exp Dermatol.
2002;27(7):585–590.
[43] Gottlieb AB. Psoriasis: emerging therapeutic strate-
gies. Nat Rev Drug Discov. 2005;4(1):19–34.